Abstract
Genome sequencing of relapsed, invasive lobular breast cancer identified actionable mutations in 86% of the cases. HER2 alterations occur in 27% of the cases, including 4 cases with activating HER2 mutations and 1 with a novel HER2-GRB7 gene fusion. This fusion links the HER2 tyrosine kinase domain to the GRB7 src homology 2 (SH2) domain.
Original language | English |
---|---|
Pages (from-to) | 3331-3333 |
Number of pages | 3 |
Journal | Clinical Cancer Research |
Volume | 19 |
Issue number | 13 |
DOIs | |
State | Published - Jul 1 2013 |